首页> 美国卫生研究院文献>Frontiers in Endocrinology >Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?
【2h】

Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?

机译:首次尝试失败后催乳素瘤患者接受卡麦角林的第二次尝试:值得吗?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Successful discontinuation of cabergoline (CAB) treatment has been reported in 31–75% of prolactinomas patients treated for at least 2 years. In contrast, it is not well established whether CAB therapy can be successfully withdrawn after a failed first attempt. This prospective open trial was designed to address this topic and to try to identify possible predictor factors. Among 180 patients with prolactinomas on CAB therapy, the authors selected those who fulfilled very strict criteria, particularly additional CAB therapy for at least 2 years, normalization of serum prolactin (PRL) levels following CAB restart, no tumor remnant >10 mm, no previous pituitary radiotherapy or surgery; and current CAB dose ≤1.0 mg/week. Recurrence was defined as an increase of PRL levels above the upper limit of normal. A total of 34 patients (70.6% female) treated with CAB for 24–30 months were recruited. Ten patients (29.4%) remained without evidence of recurrence after 24–26 months of follow-up. Twenty-four patients (70.6%) recurred within 15 months (75% within 12 months) after drug withdrawal and ~80% were restarted CAB. Median time to recurrence was 10.5 months (range, 3–15). Despite overlapping values, non-recurring patients had significantly lower mean PRL levels before withdrawal. Moreover, the recurrence rate was lower in subjects without visible tumor on pituitary magnetic resonance imaging (MRI) than in those with small remnant tumor (60 vs. 79%), though the difference was not statistically significant (P = 0.20). No other characteristic could be identified as a predictor of successful CAB discontinuation. In conclusion, a second attempt of CAB withdrawal after two additional years of therapy may be successful, particularly in patients with lower PRL levels and no visible tumor on pituitary MRI. Close monitoring of PRL level is mandatory, especially within the first year after withdrawal, where most recurrences are detected.
机译:据报道,接受至少2年治疗的泌乳素瘤患者中有31–75%成功停用了卡麦角林(CAB)治疗。相反,在首次尝试失败后能否成功撤出CAB治疗尚无定论。这项前瞻性开放试验旨在解决该主题并尝试确定可能的预测因素。在180例接受CAB治疗的泌乳素瘤患者中,作者选择了符合非常严格标准的患者,尤其是至少进行了2年的CAB治疗,CAB重新开始后血清催乳素(PRL)水平恢复正常,无肿瘤残留> 10mm,无垂体放疗或手术;目前的CAB剂量≤1.0μmg/周。复发定义为PRL水平升高至正常上限以上。总共招募了34名接受CAB治疗24-30个月的患者(女性为70.6%)。随访24-26个月后,仍有10例患者(29.4%)没有复发的迹象。停药后15个月内有24例患者(70.6%)复发(12个月内有75%复发),约80%的患者重新开始CAB。复发的中位时间为10.5个月(范围3-15)。尽管数值重叠,但非复发患者在退出治疗前的平均PRL水平明显较低。此外,在垂体磁共振成像(MRI)上无可见肿瘤的受试者中,其复发率低于具有小残留肿瘤的受试者(60%vs. 79%),尽管差异无统计学意义(P = 0.20)。没有其他特征可以确定为成功终止CAB的预测因素。总之,经过两年的治疗后,CAB撤药的第二次尝试可能是成功的,特别是对于PRL水平较低且垂体MRI上没有可见肿瘤的患者。必须严格监控PRL水平,尤其是在戒断后的第一年内,其中大多数复发被发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号